TICKERNERD
Menu
IARTIARTHealthcare · Medical Devices

IART Stock Forecast: Integra LifeSciences Holdings Corp. Price Predictions for 2026-2027

Last close, 4 Sept 2026
$17
+1.70% on the day

The 12 Wall Street analysts covering Integra LifeSciences Holdings Corp. hold a median 12-month price target of $19 — +13.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 5 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$1.3B
Ticker Nerd rank
88 / 100
Median analyst target
$19
Analysts covering
12
Revenue$418.8M+0.8% y/y
Operating income$19.3M
Net income$4.5M
Free cash flow$10.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.0%
1M
−6.6%
YTD
+34.6%
1Y
+6.8%
From 52W high
−15.8%
From 52W low
+87.9%
$9
$20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IART stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Integra LifeSciences Holdings Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 5 Sept 2026
88 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
92
Value
90
Revisions
78
Momentum
65
Issuance
63
Accruals
60
Quality
53
Volatility
43
Size
42

Growth (92): Sales and profits are climbing, and climbing faster than before.

Volatility (43): The share price moves around a lot.

Size (42): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IART stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IART, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26IARTHigh $27Median $19Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
3 Buy7 Hold2 Sell
Low $14Median $19High $27

The green dot is the last close — the median target sits +13.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
30 July 2026Wells FargoMaintainsEqual-Weight$15 → $18
28 July 2026UBSInitiatesNeutral$19
16 July 2026Truist SecuritiesMaintainsHold$14 → $19
16 July 2026Truist SecuritiesMaintainsHold—
9 July 2026BMO CapitalInitiatesMarket Perform$19
9 July 2026BMO CapitalInitiatesMarket Perform—
8 July 2026CitigroupMaintainsNeutral$16 → $19
8 July 2026CitigroupMaintainsNeutral—
28 May 2026CitigroupUpgradeNeutral—
6 May 2026CitigroupMaintainsSell—
6 May 2026Wells FargoMaintainsEqual-Weight—
15 Apr 2026Argus ResearchDowngradeHold—
15 Apr 2026Truist SecuritiesMaintainsHold—
11 Mar 2026CitigroupMaintainsSell—
27 Feb 2026Wells FargoMaintainsEqual-Weight—
3 Nov 2025Truist SecuritiesReiteratesHold—
31 Oct 2025CitigroupMaintainsSell—
31 Oct 2025JP MorganMaintainsUnderweight—
15 Oct 2025Truist SecuritiesMaintainsHold—
7 Oct 2025CitigroupMaintainsSell—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IART appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IART vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Sept 2026, Integra LifeSciences Holdings Corp. returned +6.8% against +20.0% for the S&P 500, dividends included.

IART vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Oct 25Jan 26Apr 26Jul 26IARTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IART analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.3%
Analysts raising
5
Analysts cutting
0
Fundamentals

Integra LifeSciences Holdings Corp. (IART) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
66.5×

Cheaper than 11% of US stocks

Price / sales
0.8×

Cheaper than 75% of US stocks

Price / book
1.2×

Cheaper than 67% of US stocks

EV / EBITDA
9.7×

Cheaper than 40% of US stocks

Growth & margins
Revenue growth (YoY)
0.8%

Higher than 29% of US stocks

Earnings growth (YoY)
0.8%

Higher than 36% of US stocks

Gross margin
52.5%

Higher than 65% of US stocks

Operating margin
9.6%

Higher than 64% of US stocks

Net margin
−0.4%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−0.7%

Higher than 43% of US stocks

Return on assets
2.8%

Higher than 64% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Integra LifeSciences Holdings Corp. (IART) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Integra LifeSciences Holdings Corp. has a market value of $1.3B and an enterprise value of $3.1B.

  • Revenue in the twelve months to 30 June 2026: $1.6B. The latest quarter grew 0.8% year on year.

  • Net income over the same four quarters: −$7.2M, a −0.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.09.

  • Free cash flow in the twelve months to 30 June 2026: $11.6M.

  • Shares outstanding: 77.8M.

  • Trailing P/E: 66.5×; forward P/E: 6.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Integra LifeSciences Holdings Corp. employs 4,427 people — $372K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Sept 2026

Data provided by Twelve Data

Peers

IART vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
IARTIntegra LifeSciences Holdings Corp.$1.3B
88
PRCTPROCEPT BioRobotics Corp.$1.3B
39
AORTArtivion, Inc.$1.2B
43
TNDMTandem Diabetes Care, Inc.$1.4B
66
ATECAlphatec Holdings, Inc.$1.4B
72
BVSBioventus, Inc.$1.2B
98
LMRILumexa Imaging Holdings, Inc.$1.2B
2

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Integra LifeSciences Holdings Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IART news & analysis

Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference

GlobeNewsWire · 4 Sept 2026neutral

Integra LifeSciences announced that CFO Lea Knight and CCO Michael McBreen will present at the 2026 Wells Fargo Healthcare Conference on September 9, 2026, and that Chairman and CEO Stuart Essig will present at the 2026 Morgan Stanley Healthcare Conference on September 15, 2026.

Why it matters — IART watchers would care because these scheduled presentations give the company's executives a platform to discuss the business with the investment community at two major healthcare conferences.

Integra LifeSciences: Strong Q2 2026 Results Support Recovery Thesis

Seeking Alpha · 2 Sept 2026positive

Integra LifeSciences reported strong second-quarter 2026 results with margin expansion, led by its specialty surgery segment. Tissue reconstruction declined but was offset by a successful PriMatrix relaunch and an upcoming SurgiMend reintroduction, while management targets reducing leverage to 2.5-3.5x by the end of 2026 through debt repayment.

Why it matters — The earnings beat, margin expansion, and improving cash flow with a stated deleveraging plan signal ongoing progress in what the article describes as a turnaround for IART.

Integra (IART) Down 1.6% Since Last Earnings Report: Can It Rebound?

Zacks Investment Research · 28 Aug 2026neutral

Integra LifeSciences (IART) reported earnings 30 days ago, and its stock has declined 1.6% since that report. The article raises the question of whether the stock can rebound and what may come next for the company.

Why it matters — An IART watcher would care because the article focuses on the stock's post-earnings performance and what may drive its next move.

Why Integra LifeSciences (IART) is a Top Value Stock for the Long-Term

Zacks Investment Research · 27 Aug 2026positive

Zacks Investment Research highlights Integra LifeSciences (IART) as a top value stock for the long term, noting that its Style Scores feature helps investors identify strong stocks regardless of their investing style.

Why it matters — This positive recognition from a research service could draw attention to IART as a long-term value pick for investors tracking the company.

Can IART's SurgiMend Relaunch Help Drive a Broader 2027 Recovery?

Zacks Investment Research · 20 Aug 2026neutral

According to Zacks Investment Research, Integra's SurgiMend relaunch could support a broader 2027 recovery, though customer recapture and FDA approval remain key to the potential upside.

Why it matters — A IART watcher would care because SurgiMend's relaunch and regulatory progress are central to the company's anticipated recovery trajectory.

FAQ

Frequently asked questions about IART stock

What is the IART stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Integra LifeSciences Holdings Corp. have a median 12-month price target of $19, with estimates ranging from $14 to $27. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IART stock a buy right now?

Of the 12 analysts covering Integra LifeSciences Holdings Corp., 3 rate it a Buy, 7 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Integra LifeSciences Holdings Corp. 88 out of 100 across roughly 4,600 US stocks as at 5 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IART?

As at 5 Sept 2026, Integra LifeSciences Holdings Corp. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (92 of 100).

Will IART stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +13.6% from the last close, and Ticker Nerd's factor model ranks Integra LifeSciences Holdings Corp. 88 out of 100 as at 5 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IART stock forecast for 2030?

No analyst covering Integra LifeSciences Holdings Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IART are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $27 over the next 12 months.

How has IART stock performed over the past year?

Integra LifeSciences Holdings Corp. returned +6.8% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Integra LifeSciences Holdings Corp. do?

Integra LifeSciences Holdings Corporation is a medical technology company that develops, manufactures, and markets products used in neurosurgery, regenerative medicine, and surgical reconstruction. The company’s current business is organized around two main segments, Codman Specialty Surgical and Tissue Technologies, which support procedures in neurosurgery, neurocritical care, otolaryngology, wound repair, and tissue reconstruction.

What is the latest news on IART?

The most recent item we track (GlobeNewsWire, 4 Sept 2026): "Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference". Integra LifeSciences announced that CFO Lea Knight and CCO Michael McBreen will present at the 2026 Wells Fargo Healthcare Conference on September 9, 2026, and that Chairman and CEO Stuart Essig will present at the 2026 Morgan Stanley Healthcare Conference on September 15, 2026.

Company

About Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation is a medical technology company that develops, manufactures, and markets products used in neurosurgery, regenerative medicine, and surgical reconstruction. The company’s current business is organized around two main segments, Codman Specialty Surgical and Tissue Technologies, which support procedures in neurosurgery, neurocritical care, otolaryngology, wound repair, and tissue reconstruction. Its portfolio includes surgical instruments, dural repair products, cerebrospinal fluid management devices, cranial stabilization tools, and regenerative tissue technologies designed for complex wound and reconstructive care. Integra LifeSciences Holdings Corporation serves hospitals, surgery centers, and specialist clinicians across a range of medical disciplines, making it an important supplier in the healthcare equipment market. Headquartered in Princeton, New Jersey, the company focuses on providing clinically oriented solutions for procedures that require precision, reliability, and specialized surgical support.

CEO Dr. Stuart M. Essig Ph.D. · 4,427 employees · United States · https://www.integralife.com